Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer-Reference-Cited by-同舟云学术

Weekly Docetaxel and Vinorelbine (VIN-DOX) as First Line Treatment in Patients with Hormone Refractory Prostate Cancer

Published:2004-12 Issue:6 Volume:46 Page:712-716
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Di Lorenzo Giuseppe,Pizza Carmine,Autorino Riccardo,De Laurentiis Michele,Marano Ombretta,D’Alessio Adele,Cancello Giuseppe,Altieri Vincenzo,Tortora Giampaolo,Perdonà Sisto,Bianco Angelo Raffaele,De Placido Sabino

Publisher

Elsevier BV

Subject

Urology

Reference34 articles.

1. Cancer statistics;Jemal;CA Cancer J Clin.,2003

2. Managment of advanced prostate cancer;Auclerc;Oncologist.,2000

3. Phase I/II studies of docetaxel (taxotere) combined with estramustine in men with hormone refractory prostate cancer;Petrylak;Semin. Oncol,1999

4. Phase II study of docetaxel, estramustine and low dose hydrocortisone in men with hormone refractory prostate cancer: a final report of CALGB9780;Savarese;J Clin Oncol.,2001

5. Preliminary evaluation of shorte corse of estramustine phosphate and docetaxel in hormone refractory prostate cancer;Sinibaldi;Semin Oncol,1999

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNF7 knockdown inhibits prostate cancer tumorigenesis by inactivation of ERK1/2 pathway;Scientific Reports;2017-03-02

2. Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer—going beyond PSA and imaging, a systematic literature review;Annals of Oncology;2015-11

3. Tubulin-Targeting Agents in Hybrid Drugs;Current Medicinal Chemistry;2010-03-01

4. Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life;Anti-Cancer Drugs;2008-07

5. Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study;European Urology;2007-10